Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation

Nature Genetics

Volumn 45, Issue 3, 2013, Pages 253-261

  Morris, Luc G T ^a   Kaufman, Andrew M ^a   Gong, Yongxing ^a   Ramaswami, Deepa ^a   Walsh, Logan A ^a   Turcan, Şevin ^a   Eng, Stephanie ^a   Kannan, Kasthuri ^a   Zou, Yilong ^a   Peng, Luke ^a   Banuchi, Victoria E ^a   Paty, Phillip ^a   Zeng, Zhaoshi ^a   Vakiani, Efsevia ^a   Solit, David ^a   Singh, Bhuvanesh ^a   Ganly, Ian ^a   Liau, Linda ^b   Cloughesy, Timothy C ^b   Mischel, Paul S ^b   Mellinghoff, Ingo K ^a   Chan, Timothy A ^a   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAT1 PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME DELETION 4; CHROMOSOME DELETION 4Q35; COLORECTAL CANCER; CONTROLLED STUDY; DROSOPHILA MELANOGASTER; GENE INACTIVATION; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN INDUCTION; SOMATIC MUTATION; WNT SIGNALING PATHWAY;

ANIMALS; CADHERINS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMES, HUMAN, PAIR 4; DISEASE MODELS, ANIMAL; DROSOPHILA MELANOGASTER; DROSOPHILA PROTEINS; HUMANS; MUTATION; NEOPLASMS; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; WNT SIGNALING PATHWAY;

DROSOPHILA MELANOGASTER;

EID: 84874645357     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.2538     Document Type: Article

References (92)

1. Borkosky, SS. et al. Frequent deletion of ING2 locus at 4q35.1 associates with advanced tumor stage in head and neck squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 135, 703-713 (2009
2. Brosens, RP. et al. Deletion of chromosome 4q predicts outcome in stage II colon cancer patients. Anal. Cell Pathol. (Amst.) 33, 95-104 (2010
3. Nakamura, E. et al. Frequent silencing of a putative tumor suppressor gene melatonin receptor 1 A (MTNR1A) in oral squamous-cell carcinoma. Cancer Sci. 99, 1390-1400 (2008
4. Nakaya, K. et al. Identification of homozygous deletions of tumor suppressor gene FAT in oral cancer using CGH-Array. Oncogene 26, 5300-5308 (2007
5. TCGA. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008
6. Singh, RK. et al. Deletions in chromosome 4 differentially associated with the development of cervical cancer: Evidence of slit2 as a candidate tumor suppressor gene. Hum. Genet. 122, 71-81 (2007
7. Katoh, Y. & Katoh, M. Comparative integromics on FAT1, FAT2, FAT3 and FAT4. Int. J. Mol. Med. 18, 523-528 (2006
8. Skouloudaki, K. et al. Scribble participates in Hippo signaling and is required for normal zebrafish pronephros development. Proc. Natl. Acad. Sci. USA 106, 8579-8584 (2009
9. Tanoue, T. & Takeichi, M. New insights into Fat cadherins. J. Cell Sci. 118, 2347-2353 (2005
10. Tanoue, T. & Takeichi, M. Mammalian Fat1 cadherin regulates actin dynamics and cell-cell contact. J. Cell Biol. 165, 517-528 (2004
11. Bryant, PJ., Huettner, B., Held, LI. Jr., Ryerse, J. & Szidonya, J. Mutations at the fat locus interfere with cell proliferation control and epithelial morphogenesis in Drosophila. Dev. Biol. 129, 541-554 (1988
12. Mahoney, PA. et al. The fat tumor suppressor gene in Drosophila encodes a novel member of the cadherin gene superfamily. Cell 67, 853-868 (1991
13. Mao, Y. et al. Characterization of a Dchs1 mutant mouse reveals requirements for Dchs1-Fat4 signaling during mammalian development. Development 138, 947-957 (2011
14. Saburi, S., Hester, I., Goodrich, L. & McNeill, H. Functional interactions between Fat family cadherins in tissue morphogenesis and planar polarity. Development 139, 1806-1820 (2012
15. Qi, C., Zhu, YT., Hu, L. & Zhu, YJ. Identification of Fat4 as a candidate tumor suppressor gene in breast cancers. Int. J. Cancer 124, 793-798 (2009
16. Saburi, S. et al. Loss of Fat4 disrupts PCP signaling and oriented cell division and leads to cystic kidney disease. Nat. Genet. 40, 1010-1015 (2008
17. Ishiuchi, T., Misaki, K., Yonemura, S., Takeichi, M. & Tanoue, T. Mammalian Fat and Dachsous cadherins regulate apical membrane organization in the embryonic cerebral cortex. J. Cell Biol. 185, 959-967 (2009
18. Castillejo-López, C., Arias, WM. & Baumgartner, S. The fat-like gene of Drosophila is the true orthologue of vertebrate fat cadherins and is involved in the formation of tubular organs. J. Biol. Chem. 279, 24034-24043 (2004
19. Ciani, L., Patel, A., Allen, ND. & ffrench-Constant, C. Mice lacking the giant protocadherin mFAT1 exhibit renal slit junction abnormalities and a partially penetrant cyclopia and anophthalmia phenotype. Mol. Cell Biol. 23, 3575-3582 (2003
20. Halder, G. & Johnson, RL. Hippo signaling: Growth control and beyond. Development 138, 9-22 (2011
21. Rock, R., Schrauth, S. & Gessler, M. Expression of mouse dchs1, fjx1, and fat-j suggests conservation of the planar cell polarity pathway identified in Drosophila. Dev. Dyn. 234, 747-755 (2005
22. Behrens, J. et al. Functional interaction of β-catenin with the transcription factor LEF-1. Nature 382, 638-642 (1996
23. Clevers, H. Wnt/β-catenin signaling in development and disease. Cell 127, 469-480 (2006
24. Lustig, B. & Behrens, J. The Wnt signaling pathway and its role in tumor development. J. Cancer Res. Clin. Oncol. 129, 199-221 (2003
25. Reya, T. & Clevers, H. Wnt signalling in stem cells and cancer. Nature 434, 843-850 (2005
26. Zechner, D. β-catenin signals regulate cell growth and the balance between progenitor cell expansion and differentiation in the nervous system. Dev. Biol. 258, 406-418 (2003
27. Liu, W. et al. Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating β-catenin/TCF signalling. Nat. Genet. 26, 146-147 (2000
28. Miyoshi, Y. et al. Somatic mutations of the APC gene in colorectal tumors: Mutation cluster region in the APC gene. Hum. Mol. Genet. 1, 229-233 (1992
29. Ilyas, M., Tomlinson, IP., Rowan, A., Pignatelli, M. & Bodmer, WF. β-catenin mutations in cell lines established from human colorectal cancers. Proc. Natl. Acad. Sci. USA 94, 10330-10334 (1997
30. Korinek, V. et al. Constitutive transcriptional activation by a β-catenin-Tcf complex in APC/colon carcinoma. Science 275, 1784-1787 (1997
31. Morin, PJ. et al. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 275, 1787-1790 (1997
32. Sadot, E., Simcha, I., Shtutman, M., Ben-Ze'ev, A. & Geiger, B. Inhibition of β-catenin-mediated transactivation by cadherin derivatives. Proc. Natl. Acad. Sci. USA 95, 15339-15344 (1998
33. Simcha, I. et al. Cadherin sequences that inhibit β-catenin signaling: A study in yeast and mammalian cells. Mol. Biol. Cell 12, 1177-1188 (2001
34. Takeichi, M. Morphogenetic roles of classic cadherins. Curr. Opin. Cell Biol. 7, 619-627 (1995
35. Hou, R., Liu, L., Anees, S., Hiroyasu, S. & Sibinga, NE. The Fat1 cadherin integrates vascular smooth muscle cell growth and migration signals. J. Cell Biol. 173, 417-429 (2006
36. Simcha, I. et al. Differential nuclear translocation and transactivation potential of β-catenin and plakoglobin. J. Cell Biol. 141, 1433-1448 (1998
37. Molenaar, M. et al. XTcf-3 transcription factor mediates β-catenin-induced axis formation in Xenopus embryos. Cell 86, 391-399 (1996
38. Jung, HC. & Kim, K. Identification of MYCBP as a β-catenin/LEF-1 target using DNA microarray analysis. Life Sci. 77, 1249-1262 (2005
39. Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899-905 (2010
40. Sherry, ST. et al. dbSNP: The NCBI database of genetic variation. Nucleic Acids Res. 29, 308-311 (2001
41. Adzhubei, IA. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248-249 (2010
42. Sonoda, Y. et al. Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res. 61, 4956-4960 (2001
43. Clark, MJ. et al. U87MG decoded: The genomic sequence of a cytogenetically aberrant human cancer cell line. PLoS Genet. 6, e1000832 (2010
44. Vistejnova, L. et al. The comparison of impedance-based method of cell proliferation monitoring with commonly used metabolic-based techniques. Neuroendocrinol. Lett. 30 (SUPPL1), 121-127 (2009
45. Ke, N. The xCELLigence system for real-Time and label-free monitoring of cell viability. Methods Mol. Biol. 740, 33-43 (2011
46. Dunne, J. et al. Molecular cloning and tissue expression of FAT, the human homologue of the Drosophila fat gene that is located on chromosome 4q34-q35 and encodes a putative adhesion molecule. Genomics 30, 207-223 (1995
47. Chan, TA., Wang, Z., Dang, LH., Vogelstein, B. & Kinzler, KW. Targeted inactivation of CTNNB1 reveals unexpected effects of β-catenin mutation. Proc. Natl. Acad. Sci. USA 99, 8265-8270 (2002
48. Schmalhofer, O., Brabletz, S. & Brabletz, T. E-cadherin, β-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 28, 151-166 (2009
49. Kolligs, FT. et al. ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with β-catenin defects and promotes neoplastic transformation. Cancer Cell 1, 145-155 (2002
50. Rockman, SP. et al. Id2 is a target of the β-catenin/T cell factor pathway in colon carcinoma. J. Biol. Chem. 276, 45113-45119 (2001
51. Dohadwala, M. et al. Cyclooxygenase-2-dependent regulation of E-cadherin: Prostaglandin E2 induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res. 66, 5338-5345 (2006
52. He, TC. et al. Identification of c-MYC as a target of the APC pathway. Science 281, 1509-1512 (1998
53. Miwa, N. et al. Involvement of claudin-1 in the β-catenin/Tcf signaling pathway and its frequent upregulation in human colorectal cancers. Oncol. Res. 12, 469-476 (2001
54. Onder, TT. et al. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 68, 3645-3654 (2008
55. Fujii, M. et al. TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth. J. Exp. Med. 209, 479-494 (2012
56. Huang, J., Wu, S., Barrera, J., Matthews, K. & Pan, D. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila homolog of YAP. Cell 122, 421-434 (2005
57. Zhang, J. et al. YAP-dependent induction of amphiregulin identifies a non-cell-Autonomous component of the Hippo pathway. Nat. Cell Biol. 11, 1444-1450 (2009
58. Zhao, B., Li, L. & Guan, KL. Hippo signaling at a glance. J. Cell Sci. 123, 4001-4006 (2010
59. Verhaak, RG. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98-110 (2010
60. TCGA. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011
61. Orsulic, S., Huber, O., Aberle, H., Arnold, S. & Kemler, R. E-cadherin binding prevents β-catenin nuclear localization and β-catenin/LEF-1-mediated transactivation. J. Cell Sci. 112, 1237-1245 (1999
62. Saldanha, G., Ghura, V., Potter, L. & Fletcher, A. Nuclear β-catenin in basal cell carcinoma correlates with increased proliferation. Br. J. Dermatol. 151, 157-164 (2004
63. Gottardi, CJ., Wong, E. & Gumbiner, BM. E-cadherin suppresses cellular transformation by inhibiting β-catenin signaling in an adhesion-independent manner. J. Cell Biol. 153, 1049-1060 (2001
64. Venkiteswaran, K. et al. Regulation of endothelial barrier function and growth by VE-cadherin, plakoglobin, and β-catenin. Am. J. Physiol. Cell Physiol. 283, C811-C821 (2002
65. Wong, AS. & Gumbiner, BM. Adhesion-independent mechanism for suppression of tumor cell invasion by E-cadherin. J. Cell Biol. 161, 1191-1203 (2003
66. Katz, BZ., Levenberg, S., Yamada, KM. & Geiger, B. Modulation of cell-cell adherens junctions by surface clustering of the N-cadherin cytoplasmic tail. Exp. Cell Res. 243, 415-424 (1998
67. Agrawal, N. et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333, 1154-1157 (2011
68. Candidus, S., Bischoff, P., Becker, KF. & Hofler, H. No evidence for mutations in the α-And β-catenin genes in human gastric and breast carcinomas. Cancer Res. 56, 49-52 (1996
69. Stransky, N. et al. The mutational landscape of head and neck squamous cell carcinoma. Science 333, 1157-1160 (2011
70. Bafico, A., Liu, G., Goldin, L., Harris, V. & Aaronson, SA. An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell 6, 497-506 (2004
71. Wang, L. et al. Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and β-catenin stabilization. Cancer Cell 15, 207-219 (2009
72. Aguilera, O. et al. Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene 25, 4116-4121 (2006
73. Caldwell, GM. et al. The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res. 64, 883-888 (2004
74. Kongkham, PN. et al. The SFRP family of WNT inhibitors function as novel tumor suppressor genes epigenetically silenced in medulloblastoma. Oncogene 29, 3017-3024 (2010
75. Nojima, M. et al. Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer. Oncogene 26, 4699-4713 (2007
76. Suzuki, H. et al. Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br. J. Cancer 98, 1147-1156 (2008
77. Suzuki, H. et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat. Genet. 36, 417-422 (2004
78. Baylin, SB. & Ohm, JE. Epigenetic gene silencing in cancer -A mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer 6, 107-116 (2006
79. Getz, G. et al. Comment on "The consensus coding sequences of human breast and colorectal cancers". Science 317, 1500 (2007
80. Parsons, DW. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812 (2008
81. Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806 (2008
82. Cahill, DP. et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin. Cancer Res. 13, 2038-2045 (2007
83. Hunter, C. et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res. 66, 3987-3991 (2006
84. Janakiraman, M. et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res. 70, 5901-5911 (2010
85. Beroukhim, R. et al. Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. Proc. Natl. Acad. Sci. USA 104, 20007-20012 (2007
86. Baer, M., Nilsen, TW., Costigan, C. & Altman, S. Structure and transcription of a human gene for H1 RNA, the RNA component of human RNase P. Nucleic Acids Res. 18, 97-103 (1990
87. Huang da, W., Sherman, BT. & Lempicki, RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57 (2009
88. Hosack, DA., Dennis, G. Jr., Sherman, BT., Lane, HC. & Lempicki, RA. Identifying biological themes within lists of genes with EASE. Genome Biol. 4, R70 (2003
89. Gordon, D., Abajian, C. & Green, P. Consed: A graphical tool for sequence finishing. Genome Res. 8, 195-202 (1998
90. Nickerson, DA., Tobe, VO. & Taylor, SL. PolyPhred: Automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. Nucleic Acids Res. 25, 2745-2751 (1997
91. Chen, K. et al. PolyScan: An automatic indel and SNP detection approach to the analysis of human resequencing data. Genome Res. 17, 659-666 (2007
92. Major, JE. Genomic mutation consequence calculator. Bioinformatics 23, 3091-3092 (2007